Logo

Ciphergen Reports Rise in Revenues, Smaller Loss for Q1

May 07, 2004

NEW YORK, May 7 (GenomeWeb News) - Ciphergen Biosystems yesterday reported increased revenues and narrowed losses for the first quarter of the year.

 

The company's revenues totaled $15.5 million, up from $12.8 million in the first quarter of 2003.

 

R&D costs remained flast, at $6.2 million, compared to $6.4 million during the same quarter last year.

 

Ciphergen's net loss amounted to $7.5 million, or $.26 per share, down from $9.2 million, or $.34 per share, for the year-ago period.

 

As of March 31, Ciphergen had $39.6 million in cash, cash equivalents, and investments in marketable securities.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.